Price$21.09-0.23 (-1.08%)
02:00 PM07:45 PM
News · 26 weeks81+90%
2025-12-142026-06-07
Mix4490d
- Insider26(59%)
- Other9(20%)
- SEC Filings8(18%)
- Earnings1(2%)
Latest news
25 items- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 6,214 shares at a strike of $2.39 and sold $205,149 worth of shares (9,836 units at $20.86) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- SECSEC Form 144 filed by Castle Biosciences Inc.144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
- INSIDERSEC Form 4 filed by Director Olson Tiffany4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERSEC Form 4 filed by Director Goldberg Ellen4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERSEC Form 4 filed by Director Harrison Miles4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERSEC Form 4 filed by Director Cotton Rodney4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERSEC Form 4 filed by Director Caple Kim4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERSEC Form 4 filed by Director Bradbury Daniel4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERSEC Form 4 filed by Director Cole G Bradley4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- SECCastle Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)
- INSIDERDirector Cole G Bradley converted options into 13,667 shares, increasing direct ownership by 71% to 32,976 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERDirector Bradbury Daniel converted options into 13,667 shares, increasing direct ownership by 158% to 22,340 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERDirector Harrison Miles converted options into 13,667 shares, increasing direct ownership by 62% to 35,631 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERDirector Olson Tiffany converted options into 13,667 shares, increasing direct ownership by 53% to 39,573 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERDirector Goldberg Ellen converted options into 13,667 shares, increasing direct ownership by 50% to 40,921 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERDirector Caple Kim converted options into 13,667 shares, increasing direct ownership by 61% to 36,121 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERDirector Cotton Rodney converted options into 13,667 shares, increasing direct ownership by 71% to 32,998 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERChief Commercial Officer Juvenal Tobin W exercised 11,210 shares at a strike of $3.38, increasing direct ownership by 13% to 98,035 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 550 shares at a strike of $2.39 and sold $84,066 worth of shares (4,172 units at $20.15) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Castle Biosciences Inc.SCHEDULE 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
- PRCastle Biosciences to Present at the 2026 Jefferies Global Healthcare ConferenceFRIENDSWOOD, Texas, May 13, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 1:20 p.m. Eastern time. A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website or at this link. A replay of the webcast will be available following the conclusion of the live broadcast.About Cas
- PRCastle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics InnovationThis marks the fifth MedTech Breakthrough Award that Castle has earned for its innovative testing solutionsFRIENDSWOOD, Texas, May 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its AdvanceAD-Tx test has been selected as the winner of the "Genomics Innovation Award" in the 10th annual MedTech Breakthrough Awards program, which recognizes companies driving meaningful progress and improving patient care across the global health and medical technology industry. AdvanceAD-Tx is Castle's clinically validated gene expression profile (GEP) test designed to guide systemic treatment dec
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 6,214 shares at a strike of $2.39 and sold $217,904 worth of shares (9,836 units at $22.15) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- SECSEC Form 144 filed by Castle Biosciences Inc.144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
- SECSEC Form 10-Q filed by Castle Biosciences Inc.10-Q - CASTLE BIOSCIENCES INC (0001447362) (Filer)
CSTL FAQ
7 questionsWhat does Castle Biosciences Inc. do?
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test...Where does CSTL stock trade?
Castle Biosciences Inc. (CSTL) is listed on NASDAQ.What sector and industry is CSTL in?
Castle Biosciences Inc. operates in the Health Care sector, Medical Specialities industry.When did Castle Biosciences Inc. go public?
Castle Biosciences Inc. (CSTL) completed its IPO in 2019.What are analysts saying about CSTL?
Castle Biosciences Inc. has had 5 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $2500.00 price target on 2023-12-14. Recent price targets cluster around $2500.00.What companies are similar to CSTL?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare CSTL side-by-side with any of them on Quantisnow.How can I track CSTL on Quantisnow?
Quantisnow aggregates Castle Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CSTL to receive live email and push alerts on every new disclosure.